Video Shorts

Phase 3b ENCORE: ALIS Achieves 88% Culture Conversion in MAC Lung Disease

How to Help Your Child Talk About the Effects of Their Eczema

Linaclotide’s Expanded FDA Approval for Pediatric FC Patients

Why We Must Talk to Kids About Skin Diseases

Could an OTC Supplement Prevent Post-TB Deaths?

Breakthrough in Asthma: 4 Times Greater Remission Rates with Dupilumab

The Future of HS Treatment: New Options and Innovations

Phase 3 ADVANCE OUTCOMES: 55% Reduction in PAH Events With PAH

New Phase 3 Amlitelimab Data: OX40 and Atopic Dermatitis

Phase 2 ElevAATe: Can We Normalize Alpha-1 Levels?

New Triple Agonist Drug Shows Bariatric-Level Weight Loss

World's First Dual Glucose-Ketone Monitor Receives CE Mark

Developing Lungs Highly Sensitive to Air Pollution

Discussing the Vitamin D Sunscreen Myth

Why You Shouldn't Rely Only on Office Blood Pressure Checks

Greater Eosinophils Linked to Greater Pregnancy Asthma Risk

What Phase 4 Data Shows About Tezepelumab for Asthma in Smokers

Overcoming Financial Barriers to Effective Dermatologic Care

Why Dermatologists Are Now Prescribing Weight Loss Drugs

The Biggest Obstacle in Implementing Medical AI

The Medical Sisterhood: Women Physician Role Models

The Rise of the Online-Informed Patient in Dermatology

A New Way to Manage Insulin Titration with Dexcom

The Heart Surgeon's Dilemma: Stroke Versus Bleeding Risk

Are Heart Failure Patients Being Ignored?

The Future of Eczema Treatment: 6-Month Dosing

Why Lumateperone Stands Out for Depression Treatment

Policy Advocacy: A Clinical Responsibility

Why Current Eczema Treatments Aren’t Enough

The Power of Treating Heart Health Holistically